文献速递主动脉疾病

慢性主动脉夹层行胸主动脉腔内修复术的预后

Outcomes of thoracic endovascular aortic repair for chronic aortic dissections.
PubMed 文献 · J Vasc Surg · 2017-11-20

基于VQI数据库分析125例慢性B型主动脉夹层行TEVAR的患者,中位年龄65岁,中位动脉瘤直径5.5 cm。装置成功释放率98.4%,院内死亡率2.4%,中期随访显示囊腔直径中位变化-0.2 cm;动脉瘤≥5.5 cm者更易出现囊腔缩小。

要点

  • TEVAR治疗慢性B型主动脉夹层院内死亡率2.4%,卒中0.8%,脊髓缺血症状2.4%。
  • 中位随访239天,囊腔直径中位变化-0.2 cm,27.9%患者囊腔缩小≥0.5 cm。
  • 动脉瘤≥5.5 cm者较<5.5 cm者更易出现囊腔缩小(-0.6 cm vs 0.0 cm)。

核心结论

  • TEVAR用于慢性B型主动脉夹层可接受并发症率和死亡率,中期囊腔直径变化有希望,需长期数据确定耐久性。

研究设计与样本

  • 回顾性分析VQI数据库2010年7月至2015年11月4713例TEVAR中125例慢性B型主动脉夹层修复。

主要发现

  • 中位年龄65.0岁,男性85例(68.0%),中位动脉瘤直径5.5 cm(IQR 4.8-6.3 cm)。
  • 装置成功释放123例(98.4%),中转开放手术1例(0.8%)。
  • I A型内漏2例(1.6%),I B型内漏2例(1.6%),II型内漏2例(1.6%)。
  • 围手术期并发症:卒中1例(0.8%),呼吸系统并发症6例(4.8%),出院时脊髓缺血症状3例(2.4%)。
  • 院内死亡3例(2.4%),再干预4例(1.6%假腔灌注,1.6%夹层延伸)。

临床怎么用

  • TEVAR可作为慢性B型主动脉夹层伴动脉瘤的治疗选择,需关注内漏和脊髓缺血风险。
  • 动脉瘤直径≥5.5 cm者可能更易从TEVAR中获得囊腔缩小,需长期随访评估耐久性。

局限性

  • 随访仅43例且中位时间239天,长期耐久性数据缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Open surgical repair remains the "gold standard" treatment for chronic type B aortic dissection (cTBD) with aneurysm. Thoracic endovascular aortic repair (TEVAR) has gained popularity in recent years for the treatment of thoracic aortic diseases, including cTBD. We assessed the effectiveness of TEVAR in the treatment of cTBD using the Vascular Quality Initiative (VQI) database. METHODS: The VQI registry identified 4713 patients treated with TEVAR from July 2010 to November 2015, including 125 repairs for cTBD. We analyzed TEVAR outcomes in this cohort per the Society for Vascular Surgery reporting standards for TEVAR. RESULTS: Median age was 65.0 years (interquartile range [IQR], 56.0-72.0 years), and 85 (68.0%) were male. Median aneurysm diameter was 5.5 cm (IQR, 4.8-6.3 cm). Sixty-two (49.6%) patients were asymptomatic on presentation, 57 (45.6%) were symptomatic, and 6 (4.8%) presented with rupture. Median length of stay was 8.0 days (IQR, 4.0-11.0 days). Fluoroscopy time was 17.3 minutes (IQR, 10.5-25.6 minutes). The distal landing zone was aortic zone 4 in 27 (21.6%) and aortic zone 5 and distal in 98 (78.4%) patients. Successful device delivery occurred in 123 (98.4%) patients. Conversion to open repair occurred in one (0.8%) patient. A type IA endoleak was present in 2 (1.6%), type IB endoleak in 2 (1.6%), and type II endoleak in 2 (1.6%) patients. Perioperative complications included stroke in 1 (0.8%), respiratory complications in 6 (4.8%), and spinal cord ischemia symptoms present at discharge in 3 (2.4%) patients. In-hospital mortality occurred in three (2.4%) patients. Reintervention was required in two (1.6%) patients for false lumen perfusion and in two (1.6%) patients for extension of the dissection. Follow-up was available for 43 patients at a median time of 239 days (IQR, 38-377 days). Median change in sac diameter was -0.2 cm (IQR, -0.5 to 0.1 cm). Sac shrinkage of 0.5 cm was noted in 12 (27.9%), with sac growth >0.5 cm in four (9.3%) patients. Extent of stent graft coverage did not affect sac shrinkage (P = .65). Patients with aneurysms ≥5.5 cm compared with <5.5 cm were more likely to demonstrate shrinkage (-0.6 cm vs 0.0 cm; 95% confidence interval, 0.3-11.7; P = .04). CONCLUSIONS: TEVAR for cTBD may be performed with acceptable rates of morbidity and mortality. Changes in sac diameter in the midterm are promising. Long-term data are needed to determine whether this approach is durable.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Conway AM, Qato K, Mondry LR, et al. Outcomes of thoracic endovascular aortic repair for chronic aortic dissections. J Vasc Surg. 2017. PMID: 29157682. doi:10.1016/j.jvs.2017.08.098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。